Monday, December 02, 2024 7:45:21 AM
There are numerous studies verifying Actipatch effectiveness and superiority to other pain management products.
There are also studies that show Actipatch to be ineffective. Dr. Ilfeld's recent opioid study is one. Here it is:
https://clinicaltrials.gov/study/NCT05399355?tab=results
Here's another study that shows ActiPatch to be ineffective:
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06810-y
And finally: "#2 on the breakout board" doesn't prove effectiveness or superiority. A large audience on IH for a stock that is mired at a PPS of .0003 proves that the IH community is gawking at a train wreck but not buying the stock.
ECGI Appoints AI Platform Architect as CTO to Build Mortgage Tokenization Infrastructure • ECGI • Nov 13, 2025 8:30 AM
Alliance Creative Group (ACGX) Releases 2025 Q3 Quarterly Financial and Disclosure Report • ACGX • Nov 13, 2025 4:40 AM
The Hidden Force Behind the AI Revolution • META • Nov 12, 2025 9:00 AM
The Clean Energy Breakthrough That Could Power the AI Era • MAXXF • Nov 12, 2025 9:00 AM
ECGI Highlights Fintech Expansion Through RezyFi Acquisition and Tokenized Mortgage Platform in Shareholder Letter • ECGI • Nov 11, 2025 8:30 AM
The New Gold Rush of the AI Era • ESAU • Nov 10, 2025 9:00 AM
